Axitinib
Inlyta · VEGFR TKI
Potent VEGFR-TKI; hypertension and proteinuria dominate.
Votrient · Pazo
VEGFR TKI · approved 2009 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A VEGFR tyrosine kinase inhibitor that throttles glomerular VEGF housekeeping signaling, producing the class triad of hypertension, proteinuria, and occasional renal-limited thrombotic microangiopathy.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Proteinuria is common but usually low-grade, and reported any-grade rates span roughly 15% to 80% depending on the population and how proteinuria was ascertained. In a pooled secondary analysis of two phase III trials of pazopanib or sunitinib in metastatic RCC (n=1392, Sorich 2016), any-grade proteinuria occurred in 15.0% and grade 3/4 in 3.7% — a trial adverse-event figure covering both agents, not a pazopanib-specific rate. In a single-center first-line mRCC cohort, proteinuria was reported in 80% of the pazopanib-treated patients (Land 2016), most grade 1-2 and managed with continued monitoring at the same dose. Assume proteinuria is the expectation rather than the exception on pazopanib and schedule urine protein monitoring accordingly. Hypertension is one of the most frequent class effects, with severe (grade 3-4) hypertension a recognized class risk. Thrombotic microangiopathy is rare and largely case-level; biopsy-proven renal-limited and systemic TMA/TTP-like presentations have been reported.Source: Sorich, Br J Cancer 2016 (pooled phase III, pazopanib or sunitinib); pazopanib-specific cohort reports 80% (Land, J Oncol Pharm Pract 2016)
Proteinuria and hypertension within weeks to a few months; TMA case reports within the first weeks to ~2 months.
Distilled from: “Proteinuria and hypertension typically emerge within weeks to a few months of starting therapy; TMA case reports describe onset within the first weeks to ~2 months.”
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Proteinuria from VEGF-signaling inhibition: mild/asymptomatic in ~21-63%, heavy (nephrotic-range) in up to ~6.5% of RCC patients; reflects glomerular podocyte/slit-diaphragm injury. PMID 20006922 (opens PubMed in a new tab)
Hypertension is among the most common adverse events with pazopanib in the pivotal phase III RCC trial; prospectively documented BP rise within 4 weeks of therapy. PMID 20100962 (opens PubMed in a new tab)
Uncommon; biopsy-proven drug-induced thrombotic microangiopathy reported at the case level (VEGF-inhibitor endothelial injury). PMID 33850692 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Representative incidence
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
§ Receptor target map
VEGFR2 is the target with documented renal consequences across every VEGFR TKI; multi-kinase breadth beyond it (PDGFR-β, FGFR, and off-target receptor kinases) adds further renal and hypertensive liability. Select a lit receptor for its renal consequence.
VEGFR2 · renal target
Glomerular endothelial VEGFR2: loss of podocyte-derived paracrine VEGF signaling → fenestrae loss, nephrin downregulation, nitric-oxide depletion → hypertension, proteinuria, and thrombotic microangiopathy.
Oral multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, PDGFR-alpha/beta, and c-KIT; blocks tumor angiogenesis by interrupting VEGF-driven endothelial proliferation and vascular sprouting.
Class-level context for the major non-renal toxicities of the VEGFR TKI class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. ( 5.1 )
Renal impairment — from the label
No dose adjustment is recommended for patients with renal impairment. Pazopanib tablets have not been studied in patients with severe renal impairment or in patients undergoing peritoneal dialysis or hemodialysis.
Kidney rows of the label's dosage tables
From the VOTRIENT label (Dec 2025) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Proteinuria [see Warnings and Precautions (5.14)] | 24-hour urine protein ≥ 3 grams | Withhold until improvement to Grade ≤ 1. Resume at a reduced dose (see Table 1). Permanently discontinue if 24-hour urine protein ≥ 3 grams does not improve or recurs despite dose reductions. |
1 more row naming a kidney term and an action is left out, because it could not be reproduced without guessing (a merged or blank cell, an image, or a footnote inside the text). The full table on DailyMed has it.
Everything below is FAERS — adverse events someone chose to report, about 26,971 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
6,965 of 26,971 reports
Reported with hospitalization
6,052 of 26,971 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 7,330 of the 26,971 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Pazopanib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Inlyta · VEGFR TKI
Potent VEGFR-TKI; hypertension and proteinuria dominate.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
Ofev · VEGFR/FGFR/PDGFR TKI
Proteinuria and rare TMA.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Pazopanib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Pazopanib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 42 clinical records among all 52 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.